Plain language summary: clinical trial of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis
What is this summary about? This plain language summary describes the main findings from a trial in people with idiopathic pulmonary fibrosis (also called IPF) that was recently published in the New England Journal of Medicine. IPF is a rare disease, where the lungs become more and more scarred, wit...
Saved in:
Main Authors: | Luca Richeldi (Author), Arata Azuma (Author), Vincent Cottin (Author), Christian Hesslinger (Author), Susanne Stowasser (Author), Claudia Valenzuela (Author), Marlies S Wijsenbeek (Author), Donald F Zoz (Author), Florian Voss (Author), Toby M Maher (Author) |
---|---|
Format: | Book |
Published: |
Becaris Publishing Limited,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis
by: Franziska Elena Herrmann, et al.
Published: (2022) -
Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis
by: Franziska Elena Herrmann, et al.
Published: (2023) -
Parametric Time‐to‐Event Model for Acute Exacerbations in Idiopathic Pulmonary Fibrosis
by: Fei Tang, et al.
Published: (2020) -
Lessons Learned from Developing Plain Language Summaries of Research Studies
by: Maureen Maurer, et al.
Published: (2021) -
Rational use of inhaled corticosteroids for the treatment of COPD: a plain language summary
by: Amnon Ariel, et al.
Published: (2023)